PROTHENA CORPORATION PUBLIC LIMITED COMPANY Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount
PROTHENA CORPORATION PUBLIC LIMITED COMPANY (PRTA) reported Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount of $8.77 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxCreditsResearch · last filed 2025-02-27
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY effective income tax rate reconciliation, tax credit, research, amount for fiscal 2024 was $8.77M, a 6.53% decline from fiscal 2023.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY effective income tax rate reconciliation, tax credit, research, amount for fiscal 2023 was $9.38M, a 4.84% increase from fiscal 2022.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY effective income tax rate reconciliation, tax credit, research, amount for fiscal 2022 was $8.95M, a 67.11% increase from fiscal 2021.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY effective income tax rate reconciliation, tax credit, research, amount for fiscal 2021 was $5.36M, a 92.21% increase from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 12 month |
|---|---|
| 2024-12-31 | $8.77M 10-K · filed 2025-02-27 |
| 2023-12-31 | $9.38M 10-K · filed 2025-02-27 |
| 2022-12-31 | $8.95M 10-K · filed 2025-02-27 |
| 2021-12-31 | $5.36M 10-K · filed 2024-02-22 |
| 2020-12-31 | $2.79M 10-K · filed 2023-02-28 |
| 2019-12-31 | $1.47M 10-K · filed 2022-02-25 |
| 2018-12-31 | $10.35M 10-K · filed 2021-02-26 |
| 2017-12-31 | $5.86M 10-K · filed 2020-03-03 |
| 2016-12-31 | $5.38M 10-K · filed 2019-03-15 |
| 2015-12-31 | $2.71M 10-K · filed 2018-02-26 |
| 2014-12-31 | $1.64M 10-K · filed 2017-02-27 |
| 2013-12-31 | $1.92M 10-K · filed 2016-02-25 |
| 2012-12-31 | $0.00 10-K · filed 2015-03-13 |
| 2011-12-31 | $392.00K 10-K · filed 2014-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |